Literature DB >> 6758929

Correlation of substance(s) immunologically cross-reactive with insulin, glucose and growth hormone in Hodgkin lymphoma patients.

K Pavelić, M Odavić, B Pekić, I Hrsak, S Vuk-Pavlović.   

Abstract

The levels of substance(s) detectable by insulin specific radioimmunoassay (RIA), glucose and growth hormone (GH) were determined in the blood of patients suffering from Hodgkin lymphoma. In the relapse phase of the disease, the levels of substances immunologically cross-reactive with insulin (SICRI) were elevated and glucose concentrations were below normal. In these patients the basal and hypoglycemia-induced levels of GH in blood were strongly elevated. Contrary to this, both SICRI and glucose levels were normal in the blood of patients in remission, and GH levels were significantly reduced compared to those measured in patients in relapse.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6758929     DOI: 10.1016/0304-3835(82)90112-4

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  4 in total

1.  The role of insulin-related substance in Hodgkin's disease.

Authors:  T Cabrijan; S Levanat; B Pekić; J Pavelić; R Spaventi; H Frahm; V Zjacić-Rotkvić; V Goldoni; D Vrbanec; M Misjak
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

2.  Insulin-tumour interrelationship in EL4 lymphoma or thymoma-bearing mice. I. Alloxan-diabetic or non-diabetic mice.

Authors:  D Yam; A Zilberstein; A Fink; I Nir
Journal:  Br J Cancer       Date:  1990-05       Impact factor: 7.640

3.  Modulation of insulin/IGFs pathways by sirtuin-7 inhibition in drug-induced chemoreistance.

Authors:  Ahmad Aljada; Ayman M Saleh; Salem Al Suwaidan
Journal:  Diagn Pathol       Date:  2014-05-22       Impact factor: 2.644

4.  Persistent Hypoglycemia in Patient with Hodgkin's Disease.

Authors:  Harold Cinco Lim; Lubna Bashir Munshi; David Sharon
Journal:  Case Rep Oncol Med       Date:  2015-12-29
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.